Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ensysce Biosciences (ENSC) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Ensysce Biosciences (ENSC) over the last 6 years, with Q3 2025 value amounting to 758.68%.

  • Ensysce Biosciences' EBITDA Margin fell 7775400.0% to 758.68% in Q3 2025 from the same period last year, while for Sep 2025 it was 245.89%, marking a year-over-year decrease of 1031900.0%. This contributed to the annual value of 129.18% for FY2024, which is 3513500.0% up from last year.
  • Latest data reveals that Ensysce Biosciences reported EBITDA Margin of 758.68% as of Q3 2025, which was down 7775400.0% from 127.64% recorded in Q2 2025.
  • In the past 5 years, Ensysce Biosciences' EBITDA Margin registered a high of 18.86% during Q3 2024, and its lowest value of 3400.56% during Q2 2022.
  • Its 5-year average for EBITDA Margin is 719.09%, with a median of 467.7% in 2023.
  • As far as peak fluctuations go, Ensysce Biosciences' EBITDA Margin plummeted by -33077400bps in 2022, and later skyrocketed by 29328600bps in 2023.
  • Quarter analysis of 5 years shows Ensysce Biosciences' EBITDA Margin stood at 122.71% in 2021, then crashed by -253bps to 432.57% in 2022, then tumbled by -42bps to 612.72% in 2023, then skyrocketed by 55bps to 274.34% in 2024, then plummeted by -177bps to 758.68% in 2025.
  • Its EBITDA Margin stands at 758.68% for Q3 2025, versus 127.64% for Q2 2025 and 149.08% for Q1 2025.